Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.The ...

Merck & Co has ended a second phase 3 trial of its Alzheimer’s drug, verubecestat, after an interim analysis found that it was unlikely to succeed in slowing the progression of the disease in ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...